Search Within

Sergio Andres Giralt

  1. "Oncology Research and Treatment"
Formats
  1. Meeting Abstract (5)
Groups
  1. Bone Marrow Transplant (5)
  2. Center for Hematologic Malignancies (5)
  3. Department of Medicine (5)
  4. Hematologic Malignancies, Division of (5)
Years
  1. 2024 (3)
  2. 2023 (2)
Publications
  1. Oncology Research and Treatment (5)
Publishers
  1. S. Karger AG (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3
    Meeting Abstract

    Scheid, C.; Rodriguez-Otero, P.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in the modified intent-to-treat (mITT) population
    Meeting Abstract

    Scheid, C.; Manier, S.; Ailawadhi, S.; Rodríguez-Otero, P.; Arnulf, B.; Patel, K.; Solomon, S. R.; Baz, R.; Jagannath, S.; Raje, N.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) vs standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups
    Meeting Abstract

    Raab, M. S.; Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Cavo, M.; Callander, N.; Costa, L. J.; Moreau, P.; Solomon, S. R.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Patient reported outcomes in triple class exposed, relapsed/refractory multiple myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): Idecabtagene Vicleucel (ide-cel) versus standard regimens
    Meeting Abstract

    Einsele, H.; Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T.; Arnulf, B.; Cavo, M.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (Ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 a phase 3 randomized controlled trial (RCT)
    Meeting Abstract

    Scheid, C.; Otero, P. R.; Ailawadhi, S.; Arnulf, B.; Patel, K.; Cavo, M.; Nooka, A. K.; Manier, S.; Callander, N.; Costa, L. J.; more...
    Oncology Research and Treatment (2023)

    Fulltext@MSK | Save